Positron emission tomography: A new investigational area for cancer research

Clinical Oncology

Volumn 8, Issue 1, 1996, Pages 7-14

  Wells, P ^a   Harte, R J A ^a   Price, P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; RADIOISOTOPE; TEMOZOLOMIDE;

CANCER RESEARCH; CANCER SCINTISCANNING; DRUG MECHANISM; DRUG METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REVIEW;

EID: 0029928294     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80033-0     Document Type: Review

References (48)

1. Wrenn FR, Good ML, Handler P. The use of positron-emitting radioisotopes for the localization of brain tumours. Science 1951;113:525-7.
2. Brownell GL, Sweet WH. Localization of brain tumours with positron emitters. Nucleonics 1953;11:40-5.
3. Hoffman EJ, Phleps ME, Huang SC, et al. A new tomograph for quantitative positron emission computed tomography of the brain. IEEE Trans Nucl Sci 1981;28:99-103.
4. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurements of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979;6:371-88.
5. Jones T, Chesler DA, Ter-Pogossian MM. The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man. Br J Radiol 1976;49:339-43.
6. 15O and positron emission tomography: Theory, procedure and normal values. J Comput Assist Tomogr 1980;4:727-36.
7. Lammertsma AA, Jones T. Correction for the presence of intravascular oxygen-15 in the steady state techniques for measuring regional oxygen extraction ratio in the brain: 1. Description of the method. J Cerebral Blood Flow Metab 1983;3:416-24.
8. Lammertsma AA, Wise RJS, Jones T. In vivo measurements of regional cerebral blood flow and blood volume in patients with brain tumours using positron emission tomography. Acta Neurochir 1983;69:5-13.
9. Lammertsma AA, Wise RJS, Heather JD. Correction for the presence of intravascular oxygen-15 in the steady state technique for measuring regional oxygen extraction in the brain: 2. Results in normal subjects and brain tumour and stroke patients. J Cerebral Blood Flow Metab 1983;3:425-31.
10. Lammertsma AA, Jones T. Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique: Effect on tissue heterogeneity. Br J Radiol 1992;65:697-700.
11. Lammertsma AA. Positron emission tomography and in vivo measurements of tumour perfusion and oxygen utilisation. Cancer Metastasis Rev 1987;6:521-39.
12. Beaney RP, Lammertsma AA, Jones T, etal. Positron emission tomography for in vivo measurements of regional blood flow, oxygen utilisation and blood volume in patients with breast carcinoma. Lancet 1984;i:131-4.
13. Wilson CBJH, Lammertsma AA, McKenzie CG, et al. Measurements of blood flow and exchanging water space in breast tumours using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-7.
14. Warburg O. The metabolism of tumours. London: Constable, 1930.
15. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
16. 18F]2-deoxyglucose. J. Nucl Med 1989;19:1154-61.
17. Weber G. Enzymology of cancer cells. N Engl J Med 1977;296:486-93,541-51.
18. DiChiro G, De La Paz RL, Brooks RA, et al. Glucose utilisation of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
19. 18F-2-deoxyglucose in normal and pathological cases. J Comput Assist Tomogr 1983;7:937-45.
20. 18F]fluorodeoxyglucose in brain tumours. Invest Radiol 1987;22:360-71.
21. DiChiro G, Brooks RA. PET-FDG of untreated and treated cerebral gliomas. J Nucl Med 1988;29:421-2.
22. Patronas NJ, DiChiro GD, Kufta C, et al. Prediction of survival in glioma patients by PET. J Neurosurg 1986;62:816-22.
23. Haberkorn U, Strauss LG, Reisser Ch, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumours: Relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-55.
24. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: A predictor of prognosis. Cancer 1988;6:1074-8.
25. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET in lymphoma: Proliferative activity and prognosis. In: Jawu Matsuzawa, 1994. Clinical PET in oncology. Proceedings of the Second International Symposium on PET in oncology. Sendai, Japan, World Scientific Pub, Singapore 1994.
26. Tyler JL, Diksic M, Villemur J-G, et al. Metabolic and haemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123-33.
27. Minn H, Joensuu H, Ahonen A, et al. Fluorodeoxyglucose imaging: A comparison with DNA flow cytometry in head and neck tumours. Cancer 1988;61:1776-81.
28. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabelled glucose analogue 2-[F-18]-fluoro-2-D-glucose. Radiology 1991;179:765-70.
29. Tse N, Hoh CK, Hawkins RA, et al. Application of positron emission tomography with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) to the evaluation of breast disease. Ann Surg 1992;216:27-34.
30. Wahl RL, Cody R, Zasadny K, et al. Active breast cancer chemohormonotherapy sequentially assessed by FDG PET: Early metabolic decrements precede tumour shrinkage (abstract). J Nucl Med 1991;32:982.
31. Alavi A, Smith R, Duncan D. What are the sources of error in measuring and calculating cerebral metabolic rates with fluorine-18-fluorodeoxyglucose and PET? J Nucl Med 1994;35:1466-70.
32. Minn H, Paul R. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: Frustration or future? Eur J Nucl Med 1992;19:921-4.
33. Fischman AJ, Alpert NM. FDG-PET in oncology: There's more to it than looking at pictures. J Nucl Med 1993;34:6-11.
34. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: Useful parameter of oversimplification? J Nucl Med 1994;35:1308-12.
35. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992;33:1972-80.
36. 18F-fluorodeoxyglucose In: PET. Clinical PET in oncology. Proceedings of the PET Second International Symposium on PET in oncology. Sendai, Japan, World Scientific Pub, Singapore 1994.
37. O'Reilly SM, Harte RJA, Newlands EJ, et al. Early changes in tumour glucose metabolism may predict and quantify response of gliomas to chemotherapy: A Phase II study using temozolomide [abstract]. Proc ASCO 1995;14:1635.
38. Vander Borght TM, Lambotte LE, Pauwels S, et al. Uptake of thymidine labeled on carbon 2: A potential index of liver regeneration by positron emission tomography. Hepatology 1990;12:113-8.
39. 11C]thymidine. Gastroenterology 1991;101:794-9.
40. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988;29:1633-7.
41. 3H] thyumidine uptake in rodent and canine neoplasms: Concise communication. J Nucl Med 1981;22:869-74.
42. 3H] thymidine, and gallium-67. J Nuc Med 1991;32:2118-23.
43. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, 1-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9.
44. Young D, Vine E, Ghanbarpour A, et al. Metabolic and distribution studies with radiolabelled 5-fluorouracil. J Nucl Med 1982;21:1-7.
45. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993;34:1075-81.
46. Harte RJA, O'Reilly SM, Matthews J, et al. Towards chemotherapy dose individualisation with tracer derived tissue and tumour pharmacokinetic (pk) parameters [abstract]. Proc Am Meeting ASCO 1995;14:1493.
47. Atwell GJ, Rewcastle GW, Baguley BC, et al. Potential antitumour agents: 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 1987;30:664-9.
48. Stevens MFG, Hickman JA, Langdon SP, et al. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methy-limidazo [5,1-d]-1,2,3, 5-tetrazin-4 (3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-52.